{"success":true,"data":{"pressRelease":{"id":"94990","rtpr_id":"nNFC3dz8Y1","ticker":"PHIO","exchange":"NASDAQ","all_tickers":["PHIO"],"title":"Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series","author":"Newsfile Corp","published_at":"2026-07-22T11:00:15.796Z","article_body":"Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT\n\nKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio\nPharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA\nbiopharmaceutical company developing therapeutics using its proprietary\nINTASYL(®) gene silencing technology to eliminate cancer. Phio\nPharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the\nBoard, will present an overview of the Company's INTASYL(®) siRNA platform,\nincluding its lead clinical candidate PH-762 for the treatment of cutaneous\ncarcinomas. The presentation will be followed by a live Q&A session.\n\n\"We look forward to engaging with investors at the Renmark Financial Virtual\nNon-Deal Roadshow and sharing our perspective on how INTASYL may offer a\nunique and promising approach to advancing immuno-oncology therapies,\" said\nRobert Bitterman, CEO and Chairman of Phio Pharmaceuticals.\n\nPhio's presentation and live Q&A will take place on Thursday July 28, 2026, at\n12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark\nFinancial Communications Inc.\n\nREGISTER HERE: Renmark Virtual Non-Deal Roadshow NASDAQ - PHIO | Register |\nRenmark (https://api.newsfilecorp.com/redirect/1KAK1CQrvx)\n\nPlease Note: If the link does not work, please copy and paste into your\nbrowser. To ensure smooth connectivity, please access the link above using the\nlatest version of Google Chrome.\n\nA replay of the event may be accessed on the Renmark Financial Communications\nInc. website at https://www.renmarkfinancial.com/vndrs.\n\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage\nbiopharmaceutical company advancing its proprietary INTASYL(®) siRNA gene\nsilencing technology to eliminate cancer. Phio's INTASYL compounds are\ndesigned to enhance the body's immune cells to more effectively kill cancer\ncells. Phio's lead clinical development program is an INTASYL compound,\nPH-762, that silences the PD-1 gene implicated in various forms of skin\ncancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment\nof cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.\nPH-762 is a potential non-surgical treatment for skin cancers.\n\nFor additional information, visit the Company's website, www.phiopharma.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements can be identified by words such as \"intends,\" \"believes,\"\n\"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\"\n\"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\"\n\"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not\nall forward-looking statements contain these words. These statements, which\ninclude statements, among other things, regarding the anticipated benefits of\nour INTASYL™ RNAi platform, the results from our ongoing clinical trials,\nour expectations regarding timing of FDA submissions intended to propose and\nseek guidance for next steps in clinical study design for PH-762, our\nexpectations that such FDA submissions and any related FDA meetings will\nclarify next steps in advancing the PH-762 development program, details\nregarding our planned non-clinical toxicology study, and our ability to\nsupport ongoing clinical development, operational requirements and strategic\ninitiatives with the capital we currently have on hand, are based only on our\ncurrent beliefs, expectations and assumptions and are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Our actual results may\ndiffer materially from those indicated in the forward-looking statements as a\nresult of a number of important factors, including, but not limited to, the\nimpact of future FDA interactions on the development of our product\ncandidates; the impact to our business and operations by inflationary\npressures; recession fears; the development of our product candidates, results\nfrom our nonclinical, preclinical and clinical activities, our ability to\nexecute on business strategies, our ability to develop our product candidates\nwith collaboration partners, and the success of any such collaborations, the\ntimeline and duration for advancing our product candidates into clinical\ndevelopment, the timing or likelihood of regulatory filings and approvals, the\nsuccess of our efforts to commercialize our product candidates if approved,\nour ability to manufacture and supply our product candidates for clinical\nactivities, and for commercial use if approved, the scope of protection we are\nable to establish and maintain for intellectual property rights covering our\ntechnology platform, our ability to obtain future financing, market and other\nconditions and those risks identified in our most recent Annual Report on Form\n10-K and subsequent Quarterly Reports on Form 10-Q under the caption \"Risk\nFactors\" and in other filings the Company periodically makes with the U.S.\nSecurities and Exchange Commission. Readers are urged to review these risk\nfactors and to not act in reliance on any forward-looking statements, as\nactual results may differ from those contemplated by our forward-looking\nstatements. Phio does not undertake to update forward-looking statements to\nreflect a change in its views, events or circumstances that occur after the\ndate of this release, except as required by law.\n\nContact:\nPhio Pharmaceuticals Corp.\nJennifer Phillips: jphillips@phiopharma.com\nCorporate Affairs\n\nRenmark Financial Communications Inc.\nJames R. Kautz: jkautz@renmarkfinancial.com\nTel: (416)-644-2020 or (212)-812-7680\nwww.renmarkfinancial.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/306027","article_body_html":"","raw_payload":{"data":{"id":"nNFC3dz8Y1","title":"Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series","author":"Newsfile Corp","ticker":"PHIO","created":"2026-07-22T11:00:15.796Z","tickers":["PHIO"],"exchange":"NASDAQ","article_body":"Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT\n\nKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio\nPharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA\nbiopharmaceutical company developing therapeutics using its proprietary\nINTASYL(®) gene silencing technology to eliminate cancer. Phio\nPharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the\nBoard, will present an overview of the Company's INTASYL(®) siRNA platform,\nincluding its lead clinical candidate PH-762 for the treatment of cutaneous\ncarcinomas. The presentation will be followed by a live Q&A session.\n\n\"We look forward to engaging with investors at the Renmark Financial Virtual\nNon-Deal Roadshow and sharing our perspective on how INTASYL may offer a\nunique and promising approach to advancing immuno-oncology therapies,\" said\nRobert Bitterman, CEO and Chairman of Phio Pharmaceuticals.\n\nPhio's presentation and live Q&A will take place on Thursday July 28, 2026, at\n12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark\nFinancial Communications Inc.\n\nREGISTER HERE: Renmark Virtual Non-Deal Roadshow NASDAQ - PHIO | Register |\nRenmark (https://api.newsfilecorp.com/redirect/1KAK1CQrvx)\n\nPlease Note: If the link does not work, please copy and paste into your\nbrowser. To ensure smooth connectivity, please access the link above using the\nlatest version of Google Chrome.\n\nA replay of the event may be accessed on the Renmark Financial Communications\nInc. website at https://www.renmarkfinancial.com/vndrs.\n\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage\nbiopharmaceutical company advancing its proprietary INTASYL(®) siRNA gene\nsilencing technology to eliminate cancer. Phio's INTASYL compounds are\ndesigned to enhance the body's immune cells to more effectively kill cancer\ncells. Phio's lead clinical development program is an INTASYL compound,\nPH-762, that silences the PD-1 gene implicated in various forms of skin\ncancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment\nof cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.\nPH-762 is a potential non-surgical treatment for skin cancers.\n\nFor additional information, visit the Company's website, www.phiopharma.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements can be identified by words such as \"intends,\" \"believes,\"\n\"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\"\n\"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\"\n\"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not\nall forward-looking statements contain these words. These statements, which\ninclude statements, among other things, regarding the anticipated benefits of\nour INTASYL™ RNAi platform, the results from our ongoing clinical trials,\nour expectations regarding timing of FDA submissions intended to propose and\nseek guidance for next steps in clinical study design for PH-762, our\nexpectations that such FDA submissions and any related FDA meetings will\nclarify next steps in advancing the PH-762 development program, details\nregarding our planned non-clinical toxicology study, and our ability to\nsupport ongoing clinical development, operational requirements and strategic\ninitiatives with the capital we currently have on hand, are based only on our\ncurrent beliefs, expectations and assumptions and are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Our actual results may\ndiffer materially from those indicated in the forward-looking statements as a\nresult of a number of important factors, including, but not limited to, the\nimpact of future FDA interactions on the development of our product\ncandidates; the impact to our business and operations by inflationary\npressures; recession fears; the development of our product candidates, results\nfrom our nonclinical, preclinical and clinical activities, our ability to\nexecute on business strategies, our ability to develop our product candidates\nwith collaboration partners, and the success of any such collaborations, the\ntimeline and duration for advancing our product candidates into clinical\ndevelopment, the timing or likelihood of regulatory filings and approvals, the\nsuccess of our efforts to commercialize our product candidates if approved,\nour ability to manufacture and supply our product candidates for clinical\nactivities, and for commercial use if approved, the scope of protection we are\nable to establish and maintain for intellectual property rights covering our\ntechnology platform, our ability to obtain future financing, market and other\nconditions and those risks identified in our most recent Annual Report on Form\n10-K and subsequent Quarterly Reports on Form 10-Q under the caption \"Risk\nFactors\" and in other filings the Company periodically makes with the U.S.\nSecurities and Exchange Commission. Readers are urged to review these risk\nfactors and to not act in reliance on any forward-looking statements, as\nactual results may differ from those contemplated by our forward-looking\nstatements. Phio does not undertake to update forward-looking statements to\nreflect a change in its views, events or circumstances that occur after the\ndate of this release, except as required by law.\n\nContact:\nPhio Pharmaceuticals Corp.\nJennifer Phillips: jphillips@phiopharma.com\nCorporate Affairs\n\nRenmark Financial Communications Inc.\nJames R. Kautz: jkautz@renmarkfinancial.com\nTel: (416)-644-2020 or (212)-812-7680\nwww.renmarkfinancial.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/306027"},"type":"article","timestamp":"2026-07-22T11:00:15.987478255Z","server_sent_at_ms":1784718015987},"received_at":"2026-07-22T11:00:16.037Z","source_url":"https://www.newsfilecorp.com/release/306027"},"analysis":{"id":"84032","press_release_id":"94990","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Phio Pharmaceuticals announced that CEO Robert Bitterman will present at the Renmark Financial Communications virtual non-deal roadshow on July 28, 2026.\n\nThe presentation will cover the company's INTASYL siRNA platform and its lead candidate, PH-762, which is designed to treat cutaneous carcinomas.\n\nPH-762 is currently being evaluated in a Phase 1b trial targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor roadshow announcement."},"keyFigures":{"drugName":"PH-762","customDimensions":{"clinical_trial_id":"NCT# 06014086"}},"quotedText":"We look forward to engaging with investors at the Renmark Financial Virtual Non-Deal Roadshow and sharing our perspective on how INTASYL may offer a unique and promising approach to advancing immuno-oncology therapies,","namedEntities":{"people":[{"name":"Robert Bitterman","role":"CEO and Chairman"},{"name":"Jennifer Phillips","role":"Corporate Affairs"},{"name":"James R. Kautz","role":"Renmark Financial Communications"}],"products":["INTASYL","PH-762"],"companies":[{"name":"Phio Pharmaceuticals Corp.","ticker":"PHIO"},{"name":"Renmark Financial Communications Inc.","relationship":"host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor relations announcement regarding participation in a non-deal roadshow. No new clinical data, regulatory milestones, or material financial events disclosed."},"tickerRelevance":{"others":[],"primary":"PHIO"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"investor_relations_event","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Phio Pharmaceuticals announced that CEO Robert Bitterman will present at the Renmark Financial Communications virtual non-deal roadshow on July 28, 2026.\n\nThe presentation will cover the company's INTASYL siRNA platform and its lead candidate, PH-762, which is designed to treat cutaneous carcinomas.\n\nPH-762 is currently being evaluated in a Phase 1b trial targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.","key_figures":{"drugName":"PH-762","customDimensions":{"clinical_trial_id":"NCT# 06014086"}},"named_entities":{"people":[{"name":"Robert Bitterman","role":"CEO and Chairman"},{"name":"Jennifer Phillips","role":"Corporate Affairs"},{"name":"James R. Kautz","role":"Renmark Financial Communications"}],"products":["INTASYL","PH-762"],"companies":[{"name":"Phio Pharmaceuticals Corp.","ticker":"PHIO"},{"name":"Renmark Financial Communications Inc.","relationship":"host"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-22T12:15:57.977Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"investor_relations_event","sectorWeight":"biotech"}},"durationMs":90999,"modelName":"glm-4.7"}}